"Wegovy: The Weight-Loss Wonder Drug in High Demand"

Wegovy, a weight-loss drug containing semaglutide, has seen a surge in global sales, making its manufacturer, Novo Nordisk, Europe's most valuable listed company. Despite its popularity and effectiveness in helping severely overweight individuals lose weight, there are concerns about side effects, cost, and long-term efficacy. Novo Nordisk is struggling to meet the overwhelming demand for Wegovy and is investing in expanding manufacturing capacity. The success of Wegovy has sparked an arms race in the weight-loss drug market, with other pharmaceutical companies racing to develop similar drugs.